Accelerated Restitution of Endothelial Integrity and Endothelium-Dependent Function After phVEGF 165 Gene Transfer
- 15 December 1996
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 94 (12) , 3291-3302
- https://doi.org/10.1161/01.cir.94.12.3291
Abstract
Background Delinquent reendothelialization (rET) has been shown to have a permissive, if not facilitatory, impact on smooth muscle cell proliferation. This inverse relation has been attributed to certain functions of the endothelium, including barrier regulation of permeability, thrombogenicity, and leukocyte adherence, as well as production of growth-inhibitory molecules. Accordingly, the present investigation was designed to test the hypothesis that an endothelial cell (EC) mitogen could serve as the basis for a novel gene therapy strategy designed to facilitate EC regeneration, reduce neointimal thickening, and promote recovery of EC dysfunction after balloon injury. Methods and Results New Zealand White rabbits underwent simultaneous balloon injury and gene transfer of one femoral artery with phVEGF 165 , encoding the 165–amino acid isoform of vascular endothelial growth factor (VEGF), or pGSVLacZ. In each animal transfected with phVEGF 165 or pGSVLacZ, the contralateral femoral artery was also subjected to balloon injury but not to gene transfer. For pGSVLacZ, rET remained incomplete at 4 weeks after transfection; in contrast, phVEGF 165 produced prompt rET, which was 95% complete by 1 week. Furthermore, rET in the contralateral, balloon-injured, nontransfected limb of the VEGF group was similarly accelerated. Consequently, intimal thickening was diminished, thrombotic occlusion was less frequent, and recovery of EC-dependent vasomotor reactivity was accelerated in VEGF transfectants compared with control animals. A similar benefit was observed for the contralateral, balloon-injured, nontransfected limb. Conclusions Catheter-mediated, site-specific arterial gene transfer of phVEGF 165 can accelerate rET at local and remote sites, leading to inhibition of neointimal thickening, reduction in thrombogenicity, and restoration of endothelium-dependent vasomotor reactivity. These findings support the notion that gene transfer encoding for an EC-specific mitogen may be useful for preventing the complications, including restenosis, of balloon angioplasty.Keywords
This publication has 34 references indexed in Scilit:
- Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cellsPublished by Elsevier ,2004
- Gene Therapy for Vascular Smooth Muscle Cell Proliferation After Arterial InjuryScience, 1994
- Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model.Journal of Clinical Investigation, 1994
- Proliferative activity in peripheral and coronary atherosclerotic plaque among patients undergoing percutaneous revascularization.Journal of Clinical Investigation, 1993
- Angioblast differentiation and morphogenesis of the vascular endothelium in the mouse embryoDevelopmental Biology, 1991
- Prevention of restenosis after percutaneous transluminal coronary angioplasty: The search for a “magic bullet”American Heart Journal, 1991
- Vascular Permeability Factor, an Endothelial Cell Mitogen Related to PDGFScience, 1989
- Vascular Endothelial Growth Factor Is a Secreted Angiogenic MitogenScience, 1989
- Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis.Journal of Clinical Investigation, 1989
- Morphology of the endothelium over atherosclerotic plaques in human coronary arteries.Heart, 1988